Healthcare Professionals
If you'd like to enroll patients at your site, request registration materials today.
GO

Welcome to EAPforCF.com

Learn more about the Aztreonam Lysine for Inhalation EAP

This EAP makes the investigational formulation of aztreonam lysine for inhalation available to cystic fibrosis patients with pulmonary Pseudomonas aeruginosa, who have limited or no treatment options, and who are at risk for disease progression. Patients who meet entry criteria and enroll in the program will be provided aztreonam lysine for inhalation and the eFlow® Electronic Nebulizer at no cost. Click here to review the patient eligibility criteria to see if you may have patients who are eligible for the program.

The program is open to treatment centers in the United States only. To learn more about participating, healthcare professionals may request registration materials.

Aztreonam lysine for inhalation is an investigational product, and has not yet been determined safe or efficacious in humans by the U.S. Food and Drug Administration (FDA).